RHOEN-KLINIK.UNSP.ADR 1/2 (RHKU) - Net Assets
Based on the latest financial reports, RHOEN-KLINIK.UNSP.ADR 1/2 (RHKU) has net assets worth €1.34 Billion EUR (≈ $1.57 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.86 Billion ≈ $2.18 Billion USD) and total liabilities (€523.09 Million ≈ $611.55 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of RHOEN-KLINIK.UNSP.ADR 1/2 to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.34 Billion |
| % of Total Assets | 71.93% |
| Annual Growth Rate | 2.68% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 0.63 |
RHOEN-KLINIK.UNSP.ADR 1/2 - Net Assets Trend (2021–2024)
This chart illustrates how RHOEN-KLINIK.UNSP.ADR 1/2's net assets have evolved over time, based on quarterly financial data. Also explore RHKU total assets for the complete picture of this company's asset base.
Annual Net Assets for RHOEN-KLINIK.UNSP.ADR 1/2 (2021–2024)
The table below shows the annual net assets of RHOEN-KLINIK.UNSP.ADR 1/2 from 2021 to 2024. For live valuation and market cap data, see RHKU company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €1.33 Billion ≈ $1.55 Billion |
+3.57% |
| 2023-12-31 | €1.28 Billion ≈ $1.50 Billion |
+2.30% |
| 2022-12-31 | €1.25 Billion ≈ $1.46 Billion |
+2.18% |
| 2021-12-31 | €1.22 Billion ≈ $1.43 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to RHOEN-KLINIK.UNSP.ADR 1/2's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.30 Billion | 100.00% |
| Total Equity | €1.30 Billion | 100.00% |
RHOEN-KLINIK.UNSP.ADR 1/2 Competitors by Market Cap
The table below lists competitors of RHOEN-KLINIK.UNSP.ADR 1/2 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CytomX Therapeutics Inc
NASDAQ:CTMX
|
$803.32 Million |
|
Cardinal Infrastructure Group Inc. Class A Common Stock
NASDAQ:CDNL
|
$803.49 Million |
|
Oscotec Inc
KQ:039200
|
$803.66 Million |
|
Sam Engineering Equipment
KLSE:9822
|
$803.95 Million |
|
Pantoro Limited
F:RKN
|
$803.19 Million |
|
Anhui Sierte Fertilizer Industry Ltd Co
SHE:002538
|
$803.12 Million |
|
Anyang Iron & Steel Inc
SHG:600569
|
$802.82 Million |
|
Ningbo Solartron Technology Co Ltd
SHG:688299
|
$802.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in RHOEN-KLINIK.UNSP.ADR 1/2's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,252,040,000 to 1,295,930,000, a change of 43,890,000 (3.5%).
- Net income of 43,351,000 contributed positively to equity growth.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €43.35 Million | +3.35% |
| Other Changes | €539.00K | +0.04% |
| Total Change | €- | 3.51% |
Book Value vs Market Value Analysis
This analysis compares RHOEN-KLINIK.UNSP.ADR 1/2's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.30x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €17.90 | €5.80 | x |
| 2022-12-31 | €18.28 | €5.80 | x |
| 2023-12-31 | €18.70 | €5.80 | x |
| 2024-12-31 | €19.36 | €5.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently RHOEN-KLINIK.UNSP.ADR 1/2 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.72%
- • Asset Turnover: 0.86x
- • Equity Multiplier: 1.43x
- Recent ROE (3.35%) is above the historical average (2.71%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 2.36% | 2.02% | 0.84x | 1.39x | €-91.54 Million |
| 2022 | 2.05% | 1.74% | 0.85x | 1.39x | €-97.24 Million |
| 2023 | 3.09% | 2.64% | 0.83x | 1.41x | €-86.49 Million |
| 2024 | 3.35% | 2.72% | 0.86x | 1.43x | €-86.24 Million |
Industry Comparison
This section compares RHOEN-KLINIK.UNSP.ADR 1/2's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $6,084,089,090
- Average return on equity (ROE) among peers: -85.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| RHOEN-KLINIK.UNSP.ADR 1/2 (RHKU) | €1.34 Billion | 2.36% | 0.39x | $803.26 Million |
| China Resources Medical Holdings Company Limited (1PH) | $7.00 Billion | 1.99% | 0.59x | $402.10 Million |
| AEST.MED.INT.HLD.SP.ADR/3 (3FMA) | $33.63 Million | -111.31% | 15.67x | $3.30 Million |
| JINXIN FERT.GRP HD-00001 (3NX) | $8.75 Billion | 3.88% | 0.47x | $656.44 Million |
| REVITALIST L.A.W. LTD (4DO) | $1.87 Million | -771.24% | 4.54x | $744.60K |
| Wenzhou Kangning Hospital Co. Ltd (4WK) | $1.41 Billion | 6.10% | 1.16x | $19.28 Million |
| HYGEIA HC HLDGS DL-00001 (50I) | $4.48 Billion | 9.86% | 0.49x | $11.73K |
| COMPASS PATHW SP.ADR (5Y6) | $225.74 Million | -52.48% | 0.22x | $657.30 Million |
| Bumrungrad Hospital Public Company Limited (BZ7A) | $24.10 Billion | 29.08% | 0.21x | $50.42K |
| Eifelhöhen-Klinik AG (EIF) | $18.66 Million | 24.17% | 2.10x | $10.05 Million |
| Fresenius Medical Care AG & Co. KGaA (FME) | $14.83 Billion | 3.37% | 1.29x | $10.01 Billion |
About RHOEN-KLINIK.UNSP.ADR 1/2
RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, provides in-patient, semi-patient, and outpatient healthcare services in Germany. The company also operates acute hospitals, medical care centers, and rehabilitation hospitals. RHÖN-KLINIKUM Aktiengesellschaft was founded in 1973 and is based in Bad Neustadt an der Saale, Germany.